⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28300061 | 0.98 | ALDH1A1 (0.46) | — | |
| SCHEMBL7258456 | 0.86 | MAPK1 (0.50) | — | |
| Potassium Ion SCHEMBL29436558 | 0.78 | ALDH1A1 (0.46) | — | |
| SCHEMBL48193 | 0.77 | — | — | |
| Sulfuric Acid SCHEMBL1833245 | 0.77 | ALDH1A1 (0.43) | — | |
| Sulfuric Acid SCHEMBL1833247 | 0.77 | ALDH1A1 (0.43) | — | |
| SCHEMBL1832418 | 0.77 | ALDH1A1 (0.41) | — | |
| SCHEMBL11706869 | 0.76 | ALDH1A1 (0.39) | — | |
| SCHEMBL28283415 | 0.75 | TSHR (0.47) | — | |
| SCHEMBL2424526 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109897011-A | A kind of IDO inhibitor and its application | 上海华汇拓医药科技有限公司 | 2019-06-18 | — | — | CN | claimed |
| EP-1569914-B1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2009-02-18 | — | — | EP | claimed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | claimed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | claimed |
| EP-1569914-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | Actelion Pharmaceuticals Ltd. (CH) | 2005-09-07 | — | — | EP | claimed |
| WO-2004050640-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2004-06-17 | — | — | WO | claimed |
| EP-4701735-A1 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | Nested Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250289811-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-4514471-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | Nested Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119487021-A | Heterocyclic derivatives as inhibitors of mitogen-activated protein kinase (MEK) | 内斯特治疗公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024226579-A9 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | NESTED THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024226579-A1 | HETEROCYCLIC DERIVATIVE AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITOR | NESTED THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2023211812-A1 | HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS | NESTED THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-20080292765-A1 | Sweetness Enhancers, Sweetness Enhanced Sweetener Compositions, Methods for Their Formulation, and Uses | THE COCA-COLA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080292765-A1 | Sweetness Enhancers, Sweetness Enhanced Sweetener Compositions, Methods for Their Formulation, and Uses | THE COCA-COLA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7452896-B2 | Pyrimidine-sulfamides and their use as endothelian receptor antagonist | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-11-18 | — | — | US | disclosed |
| US-20070167472-A1 | 2-Methoxy-ethanesulfamic acid [6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-5-(2-chloro-5-methoxy-phenoxy)-pyrimidin-4-yl]-amide; vasoconstrictor, mediator of cardiac, renal, endocrine functions; neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and differentiation | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1569914-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | Actelion Pharmaceuticals Ltd. (CH) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004050640-A1 | PYRIMIDINE-SULFAMIDES AND THEIR USE AS ENDOTHELIAN RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2004-06-17 | — | — | WO | disclosed |
| WO-2003082263-A1 | SULFAMIC ACIDS AS INHIBITORS OF HUMAN CYTOPLASMIC PROTEIN TYROSINE PHOSPHATASES | ONTOGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |